Bionik Laboratories (BNKL)
(Delayed Data from OTC)
$0.10 USD
0.00 (0.00%)
Updated Nov 29, 2023 09:33 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Bionik Laboratories Corp falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 2 | 1 | 1 | 2 |
Cost Of Goods | NA | 1 | 0 | 0 | 1 |
Gross Profit | NA | 1 | 1 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 6 | 11 | 7 | 12 |
Income After Depreciation & Amortization | 0 | -5 | -10 | -6 | -11 |
Non-Operating Income | NA | 0 | 0 | -7 | -14 |
Interest Expense | NA | 0 | 1 | 0 | 0 |
Pretax Income | NA | -5 | -10 | -14 | -25 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -5 | -10 | -14 | -25 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -5 | -10 | -14 | -25 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -5 | -10 | -6 | -11 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -5 | -10 | -6 | -11 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 6.90 | 5.84 | 5.13 | 4.46 |
Diluted EPS Before Non-Recurring Items | NA | -0.59 | -0.96 | -1.22 | -3.14 |
Diluted Net EPS (GAAP) | NA | -0.72 | -1.78 | -2.66 | -5.61 |
Fiscal Year end for Bionik Laboratories Corp falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 0.50 |
Cost Of Goods | NA | NA | NA | NA | 0.25 |
Gross Profit | NA | NA | NA | NA | 0.25 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 1.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -1.31 |
Non-Operating Income | NA | NA | NA | NA | -0.02 |
Interest Expense | NA | NA | NA | NA | 0.05 |
Pretax Income | NA | NA | NA | NA | -1.36 |
Income Taxes | NA | NA | NA | NA | 0.00 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | -1.36 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | -1.36 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 6.97 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.07 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | -0.20 |